Laboratory Lab results are too important to go anywhere else.

N-Telopeptide, Urine

N-Telopeptide, Urine, Collagen Crosslinks, Crosslinked N-Telopeptide of Type I Collagen, Urine, NTX Creatinine, NTx-Telopeptide, Urine

Test Codes

EPIC: LAB6115, Beaker: XNTXU, Warde: NTXUR

Department

Send Outs

Instructions

Specimen Collection Criteria

Collect (preferred specimen): Second morning void urine.

Physician Office/Draw Specimen Preparation

Maintain specimens frozen (-20°C/-4°F or below) prior to transport.

Preparation for Courier Transport

Transport: 2.0 mL second morning void urine, frozen (-20°C/-4°F or below). (Minimum: 1.0 mL)

Rejection Criteria

Specimens not collected and processed as indicated. 

In-Lab Processing

Maintain specimens refrigerated (2-8°C or 36-46°F) prior to transport.

Transport: 2.0 mL second morning void urine, frozen (-20°C/-4°F or below). (Minimum: 1.0 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 72 hours
Refrigerated (2-8°C or 36-46°F): 5 days
Frozen (-20°C/-4°F or below): 30 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Warde Medical Lab, Ann Arbor, MI and forwarded to Quest Lab, San Juan Capistrano, CA.

Performed

Monday, Wednesday, Friday.
Results available in 3-6 days.

Reference Range

By report.

Test Methodology

Chemiluminescence

Interpretation

By report.

Clinical Utility

This assay measures cross-linked N-telopeptides of collagen type 1 as an indicator of bone resorption. The Negotiated Rulemaking Committee of HCFA has listed the following indications for collagen cross-link assays (any method):

• Identifying individuals with elevated bone resorption who have osteoporosis in whom response to treatment is being monitored.
• Predicting response (as assessed by bone mass measurements) to Food and Drug Administration (FDA)-approved antiresorptive therapy in postmenopausal women.
• Assessing effectiveness of osteoporosis treatment including FDA-approved antiresorptive therapies in postmenopausal women, individuals with osteoporosis, Paget's disease of bone, and antiestrogen or selective estrogen therapies.

CPT Codes

82523 and 82570.

Contacts

Last Updated

9/16/2024